Annexon, Inc. (ANNX) Stock Price & Analysis
Annexon, Inc. (ANNX) rose 1.56% to USD 5.2 as of June 10, 2026 at 00:25 UTC, according to Nexqual real-time market data.
ANNX last closed at USD 5.12; the session ranged USD 5.02–5.34 on volume of 3,167,095 shares. Market capitalization is $851.98M, with a 52-week range of USD 1.85–7.18 (NMS). Source: Nexqual, June 10, 2026 at 00:25 UTC.
Key Statistics (as of June 10, 2026 at 00:25 UTC)
| Price | USD 5.2 |
|---|---|
| Change | ▲ 1.56% (up) |
| Previous Close | USD 5.12 |
| Open | USD 5.19 |
| Day Range | USD 5.02 – 5.34 |
| 52-Week Range | USD 1.85 – 7.18 |
| Volume | 3,167,095 shares |
| Market Cap | $851.98M |
| Exchange | NMS |
Technical Analysis (ANNX)
Nexqual's technical model rates ANNX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.79 (neutral) |
| vs SMA50 | Below (USD 5.65) |
| MACD | -0.1 (negative) |
Analyst Ratings (ANNX)
Wall Street analysts rate ANNX "Strong Buy" based on 8 analysts, with a mean price target of USD 13.13 (range USD 7–27), per Nexqual as of June 10, 2026 at 00:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 13.13 |
| High Target | USD 27 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ANNX)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.23 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.32 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.34 ▼ miss |
| 2025-06-30 | USD -0.34 vs est -0.36 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financials & Fundamentals (ANNX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -87.65% |
| Debt / Equity | 12.44 |
| Current Ratio | 6.35 |
| Total Cash | $225.02M |
| Total Debt | $25.43M |
| Free Cash Flow | $-107.34M |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financial Health Score (ANNX)
Nexqual rates Annexon, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $225M cash vs $25M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$183M |
| Efficiency | Critical — ROE -88%, ROA -45.3% |
Ownership (ANNX)
| Insider Ownership | +0.47% |
|---|---|
| Institutional Ownership | +102.71% |
| Shares Outstanding | 163.84M |
| Float | 130.11M |
| Short % of Float | +16.84% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Leadership (ANNX)
Annexon, Inc. is led by Douglas E. Love Esq. (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:25 UTC.
| CEO, President & Director | Douglas E. Love Esq. (age 57) |
|---|---|
| Executive VP, CFO & Corporate Secretary | Jennifer Lew (age 52) |
| Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | Ted Yednock (age 67) |
| Chief Scientific Officer & Executive VP | Dean R. Artis (age 64) |
| Senior Vice President of Translational Medicine | Henk-Andre Kroon |
Major Backers & Investors (ANNX)
Notable institutional backers of Annexon, Inc. include Redmile Group, LLC, FMR, LLC, BVF Inc., according to Nexqual as of June 10, 2026 at 00:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Redmile Group, LLC | 8.88% |
| FMR, LLC | 6.49% |
| BVF Inc. | 5.31% |
| Fidelity | 4.53% |
| Bain Capital Life Sciences Investors, LLC | 3.18% |
| Bellevue Group AG | 3.15% |
| MAK Capital One LLC | 2.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.27% |
| Vanguard Group | 7.2% |
| State Street | 6.83% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
From Annexon, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
- The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
- It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
- In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 1.55 | ▲ 0.65% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| NKTX | Nkarta, Inc. | USD 2.45 | ▼ 2.39% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:25 UTC. This page is informational and not investment advice.